Brand and Other Names:Dostinex
- Classes: Hyperprolactinemia
Dosing & Uses
Dosage Forms & Strengths
Hyperprolactinemic Disorders of Either Idiopathic or Pituitary Adenoma Origin
Initital:0.25 mg 2 times per week PO
May increase by 0.25 mg q4Weeks (or longer) up to 1 mg 2 times per week
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Abdominal pain (5%)
Postural hypotension (4%)
Abnormal vision (1%)
Breast pain (1%)
Hot flashes (1%)
Hypersensitivity to ergot derivatives
Severe hepatic dz
Concurrency with D2 antagonists
Women planning to nurse
Not indicated for suppression of established lactation even in Canada
History of cardiac valvular disorders as suggested by anatomical evidence of valvulopathy of any valve, determined by pretreatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis
Initial doses >1 mg may produce orthostatic hypotension
Reportedly can cause cardiac damage
- All patients should undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of valvular disease; if valvular disease is detected, the patient should not be treated with cabergoline
- Following treatment initiation, clinical and diagnostic monitoring (for example, chest x-ray, CT scan and cardiac echocardiogram) should be conducted to assess the risk of cardiac valvulopathy
- Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction or valve leaflet thickening
Pregnancy & Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
High levels in pituitary (100x of plasma)
Peak Plasma: 30-70 pg/mL following single oral doses of 0.5-1.5 mg
Protein Bound: 40-42%
Metabolism: extensively hydrolyzed
Renal Clearance: 0.08 L/min
Mechanism of Action
Dopamine receptor agonist with high affinity for D2 receptors, thereby inhibiting prolactin release
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs